Is there a significant 1-year impact on tricuspid valve regurgitation evolution in leadless-PM implanted subjects?

Abstract

Abstract Background Leadless pacemaker implanted subjects (leadless-VVI and "AV") have been shown to experience lower chronic complications and less device-related reinterventions compared to transvenous ventricular pacemakers (Transvenous-VVI, VDD) in the general PM-implanted-population. Also, conventional transvenous pacemaker ventricular leads may interfere with the tricuspid valve structures yielding significant tricuspid valve regurgitation (TR). Purpose This single-center study focusses on tricuspid valve disease to demonstrate the impact/benefits of leadless pacing at 1-year follow-up period by comparing tricuspid valve regurgitation grading at implant time and at 1-year follow-up. Methods This study is a retrospective, observational research study: 78 consecutive subjects (February 17, 2016 - January 18, 2023), treated in our Center, implanted with Micra VVI/AV leadless-PMs Micra MC1VR01 and Micra AVMC1AVR1, Medtronic, Inc., were evaluated at implant time via transthoracic echocardiography, and at 1-year follow-up period. Tricuspid valve disease was evaluated. Results See Table. Conclusion The main results from this study show that many patients at higher risk of transvenous pacemaker complications relatively to the tricuspid valve have similar tricuspid valve disease at implant time as compared to 1 year-F-up time, implicating a negligible impact of leadless pacing on the tricuspid valve compared to transvenous lead PMs.